Which ETFs hold Genmab A/S (GMAB)?
Danish biotech developing antibody medicines for cancer, including the Darzalex technology.
17 Australian ETFs hold Genmab A/S, a Health Care company from DK. ESGI has the biggest weighting at 0.62%. Across these funds, Australian ETF investors own about $26m of Genmab A/S.
The ETFs with the most Genmab A/S
All 17 ETFs that hold Genmab A/S, ranked by weight
Best-endeavours estimate. Built from each issuer's published holdings, which may be weeks or months old, may cover only part of a fund (some publish only their top 10) and are matched by company name. Figures may be incomplete or inaccurate. Check the issuer's website and PDS before relying on them. General information only.
Weights from each issuer's published holdings (September to November 2026). Some funds list only their largest holdings. General information only, not a recommendation to buy or sell Genmab A/S.
Common questions
Which ETF has the most Genmab A/S?
ESGI (VanEck MSCI International Sustainable Equity ETF) has the highest weighting, with 0.62% of the fund in Genmab A/S.
What is the cheapest ETF that holds Genmab A/S?
Of the ETFs where Genmab A/S is at least 1% of the fund, GARP has the lowest fee at 0.30% a year, with 0.22% in Genmab A/S.
How much Genmab A/S do I own with $10,000 in VEU?
About $8. VEU is the largest ETF that holds Genmab A/S, and Genmab A/S makes up 0.08% of it.
How many Australian ETFs hold Genmab A/S?
17 ETFs listed on the ASX or TMX Australia hold Genmab A/S, based on issuers' published holdings.